www.fdanews.com/articles/68250-curis-to-co-develop-cancer-drug-with-genentech-in-the-u-s
Curis to Co-Develop Cancer Drug With Genentech in the U.S.
February 1, 2005
Curis, a therapeutic drug development company, has elected to exercise a co-development option with its collaborative partner, Genentech, and will now share in U.S. development costs and future net profits, if any, derived from sales in the U.S. of a therapeutic product candidate for the topical treatment of basal cell carcinoma. Basal cell carcinoma, a skin cancer, is the most common form of all human cancers with approximately 800,000 to 1,000,000 new cases every year in the U.S.